Meta-analysis of clinical impact of onasemnogene abeparvovec treatment of spinal muscular atrophy patients

被引：0
|
作者：
Reyna, S. [1 ]
Dabbous, O. [1 ]
Wallach, S. [1 ]
Patel, A. [1 ]
Toro, W. [1 ]
Ritter, S. [1 ]
机构：
[1] Novartis Gene Therapies Inc, Bannockburn, IL USA
来源：
NEUROMUSCULAR DISORDERS | 2024年 / 43卷
关键词：
D O I：
10.1016/j.nmd.2024.07.608
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
164P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Onasemnogene abeparvovec for the treatment of spinal muscular atrophy
    McMillan, Hugh J.
    Proud, Crystal M.
    Farrar, Michelle A.
    Alexander, Ian E.
    Muntoni, Francesco
    Servais, Laurent
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (09) : 1075 - 1090
  • [2] Onasemnogene Abeparvovec in Type 1 Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis
    Pascual-Morena, Carlos
    Cavero-Redondo, Ivan
    Luceron-Lucas-Torres, Maribel
    Martinez-Garcia, Irene
    Rodriguez-Gutierrez, Eva
    Martinez-Vizcaino, Vicente
    HUMAN GENE THERAPY, 2023, 34 (3-4) : 129 - 138
  • [3] Efficacy and safety of onasemnogene abeparvovec for the treatment of patients with spinal muscular atrophy type 1: A systematic review with meta-analysis
    Fernandes, Brigida Dias
    Krug, Barbara Correa
    Rodrigues, Fernanda D'Athayde
    Cirilo, Herica Nubia Cardoso
    Borges, Stefani Sousa
    Schwartz, Ida Vanessa D.
    Probst, Livia Fernandes
    Zimmermann, Ivan
    PLOS ONE, 2024, 19 (05):
  • [4] Safety and efficacy of gene therapy with onasemnogene abeparvovec in the treatment of spinal muscular atrophy: A systematic review and meta-analysis
    Yang, Dongling
    Ruan, Yiyan
    Chen, Yuyi
    JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2023, 59 (03) : 431 - 438
  • [5] Onasemnogene Abeparvovec: A Review in Spinal Muscular Atrophy
    Hannah A. Blair
    CNS Drugs, 2022, 36 : 995 - 1005
  • [6] Onasemnogene Abeparvovec: A Review in Spinal Muscular Atrophy
    Blair, Hannah A.
    CNS DRUGS, 2022, 36 (09) : 995 - 1005
  • [7] Short-term clinical outcomes of onasemnogene abeparvovec treatment for spinal muscular atrophy
    Lee, Seungbok
    Lee, Yun Jeong
    Kong, Juhyun
    Ryu, Hye Won
    Shim, Young Kyu
    Han, Ji Yeon
    Woo, Hyewon
    Kim, Soo Yeon
    Cho, Anna
    Lim, Byung Chan
    Chae, Jong Hee
    BRAIN & DEVELOPMENT, 2022, 44 (04): : 287 - 293
  • [8] Efficacy and security of onasemnogene abeparvovec-XIOI in spinal muscular atrophy: a systematic review and meta-analysis
    Rodriguez-Calienes, Aaron
    Chavez-Malpartidaacd, Sandra
    Alvarado-Gamarra, Giancarlo
    Pacheco-Barrios, Niels
    Martinez-Esteban, Peggy
    Alva-Diaz, Carlos
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429 : 48 - 48
  • [9] Onasemnogene abeparvovec for spinal muscular atrophy: The costlier drug ever
    Mahajan, Rajiv
    INTERNATIONAL JOURNAL OF APPLIED AND BASIC MEDICAL RESEARCH, 2019, 9 (03) : 127 - 128
  • [10] Expanding the Availability of Onasemnogene Abeparvovec to Older Patients: The Evolving Treatment Landscape for Spinal Muscular Atrophy
    Rene, Charlotte A.
    Parks, Robin J.
    PHARMACEUTICS, 2023, 15 (06)
12345